ISRCTN78953383已完成不适用
Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer
Cancer Research UK (CRUK) (UK)0 个研究点目标入组 0 人开始时间: 2001年7月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Confirmed diagnosis of invasive epithelial ovarian carcinoma including the following histological subtypes: Serous cystadenocarcinoma; Mucinous cystadenocarcinoma; Endometriod carcinoma; Clear cell (mesonephroid) carcinoma; Undifferentiated carcinoma
- •2. International Federation of Gynecology and Obstetrics (FIGO) stage Ic, II, III and IV
- •3. Age 18 -70 years
- •4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •5. Life expectancy of at least 3 months
- •6. Adequate bone marrow and renal function
- •7. No previous chemotherapy or radiotherapy
- •8. No history of previous malignancy, except adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix
- •9. No serious intercurrent disease
排除标准
- •Does not match inclusion criteria
研究者
相似试验
已完成
2 期
A randomized phase II study comparing cisplatin + docetaxel with carboplatin + paclitaxel in patients with Stage III (N 2 positive) non-small-cell lung cancer who receive trimodality treatment consisting of chemoradiotherapy followed by surgery (OLCSG1601)previously untreated non-small-cell lung ccancer, stage III (N2 positive)JPRN-UMIN000024816Okayama Lung Cancer Study Group (OLCSG)80
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virusEUCTR2019-000308-13-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)180
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virusOropharyngeal Squamous Cell CarcinomaMedDRA version: 20.1Level: LLTClassification code 10079785Term: Oropharyngeal squamous cell carcinoma stage IVSystem Organ Class: 100000004864EUCTR2019-000308-13-ITEuropean Organisation for Research and Treatment of Cancer (EORTC)180
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virus.EUCTR2019-000308-13-ESEuropean Organisation for Research and Treatment of Cancer (EORTC)180
尚未招募
2 期
ANTS Trial (Australian Neoadjuvant Therapy Study for Non-small Cell Lung Cancer)ACTRN12608000061336Austin Health100